Galuppini F, Fassan M, Bertazza L, et al. - Using 125 consecutive papillary thyroid cancers (PTCs) with a median follow-up of 75.3 months, the potential role of programmed cell death 4 (PDCD4) and BRAF status as prognostic markers in PTC was investigated. The findings were validated using TGCA thyroid carcinoma dataset. Low-grade PDCD4 nuclear expression was exhibited by 59.8% of the patients. There was a correlation between low-grade expression and BRAF V600E. In univariate and multivariate analysis, researchers found a correlation of low-grade PDCD4 expression with lower levels of recurrence-free survival rate and with poor outcome. Overall, PTC outcome could be predicted by PDCD4 and an incremental impact of PDCD4 combined with BRAF alterations on the prognostic power of BRAF mutation alone was also observed.